From sprouting angiogenesis to erythrocytes generation by cancer stem cells: Evolving concepts in tumor microcirculation

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Alameddine, Raafat S ^a   Hamieh, Lana ^a   Shamseddine, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA CATENIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

ANGIOGENESIS; CANCER STEM CELL; ENDOTHELIUM; EPITHELIAL MESENCHYMAL TRANSITION; ERYTHROCYTE; HUMAN; INTUSSUSCEPTION; MICROCIRCULATION; NONHUMAN; PLASTICITY; POLYPLOID GIANT CANCER CELL; REVIEW; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; GENETICS; METABOLISM; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR EMBOLISM;

ANGIOGENESIS INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; ERYTHROCYTES; HUMANS; MICROCIRCULATION; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84922752745     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/986768     Document Type: Review

References (78)

1. Z. K. Otrock, R. A. R. Mahfouz, J. A. Makarem, and A. I. Shamseddine, "Understanding the biology of angiogenesis: review of the most important molecular mechanisms, " Blood Cells, Molecules, and Diseases, vol. 39, no. 2, pp. 212-220, 2007.
2. P. Carmeliet, "Mechanisms of angiogenesis and arteriogenesis, " Nature Medicine, vol. 6, no. 4, pp. 389-395, 2000.
3. R. S. Alameddine, Z. K. Otrock, A. Awada, and A. Shamseddine, "Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges, " Current Opinion in Oncology, vol. 25, no. 3, pp. 313-324, 2013.
4. L. B. Jakeman, M. Armanini, H. S. Phillips, and N. Ferrara, "Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis, " Endocrinology, vol. 133, no. 2, pp. 848-859, 1993.
5. N. Ferrara, H. Gerber, and J. LeCouter, "The biology of VEGF and its receptors, " Nature Medicine, vol. 9, no. 6, pp. 669-676, 2003.
6. M. J. Cross, J. Dixelius, T. Matsumoto, and L. Claesson-Welsh, "VEGF-receptor signal transduction, " Trends in Biochemical Sciences, vol. 28, no. 9, pp. 488-494, 2003.
7. G. Neufeld, S. Tessler, H. Gitay-Goren, T. Cohen, and B. Z. Levi, "Vascular endothelial growth factor and its receptors, " Progress in Growth Factor Research, vol. 5, no. 1, pp. 89-97, 1994.
8. J. D. Hood, C. J. Meininger, M. Ziche, and H. J. Granger, "VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 274, no. 3, part 2, pp. H1054-H1058, 1998.
9. K. Miller, M. Wang, J. Gralow, et al., "Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, " The New England Journal ofMedicine, vol. 357, no. 26, pp. 2666-2676, 2007.
10. R. S. Kerbel, "Tumor angiogenesis, "The New England Journal of Medicine, vol. 358, no. 19, pp. 2039-2049, 2008.
11. J. M. L. Ebos, C. R. Lee, W. Cruz-Munoz, G. A. Bjarnason, J. G. Christensen, and R. S. Kerbel, "Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis, " Cancer Cell, vol. 15, no. 3, pp. 232-239, 2009.
12. M. Pàez-Ribes, E. Allen, J. Hudock, et al., "Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis, " Cancer Cell, vol. 15, no. 3, pp. 220-231, 2009.
13. D. M. Brizel, G. S. Sibley, L. R. Prosnitz, R. L. Scher, and M. W. Dewhirst, "Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck, " International Journal of Radiation Oncology Biology Physics, vol. 38, no. 2, pp. 285-289, 1997.
14. M. Höckel, K. Schlenger, B. Aral, M. Mitze, U. Schäffer, and P. Vaupel, "Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix, " Cancer Research, vol. 56, no. 19, pp. 4509-4515, 1996.
15. S. Walenta, A. Salameh, H. Lyng, et al., "Correlation of high lactate levels in head and neck tumors with incidence of metastasis, " The American Journal of Pathology, vol. 150, no. 2, pp. 409-415, 1997.
16. G. Pitson, A. Fyles, M. Milosevic, J. Wylie, M. Pintilie, and R. Hill, "Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer, " International Journal of Radiation Oncology Biology Physics, vol. 51, no. 3, pp. 699-703, 2001.
17. J. Holash, P. C. Maisonpierre, D. Compton, et al., "Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, " Science, vol. 284, no. 5422, pp. 1994-1998, 1999.
18. T. Donnem, J. Hu, M. Ferguson, et al., "Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?" Cancer Medicine, vol. 2, no. 4, pp. 427-436, 2013.
19. P. B. Vermeulen, C. Colpaert, R. Salgado, et al., "Livermetastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia, " Journal of Pathology, vol. 195, no. 3, pp. 336-342, 2001.
20. W. P. J. Leenders, B. Küsters, K. Verrijp, et al., "Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option, " Clinical Cancer Research, vol. 10, no. 18 I, pp. 6222-6230, 2004.
21. A. D. Smith, S. N. Shah, B. I. Rini, M. L. Lieber, and E. M. Remer, "Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy, " American Journal of Roentgenology, vol. 194, no. 6, pp. 1470-1478, 2010.
22. J. C. Welti, T. Powles, S. Foo, et al., "Contrasting effects of sunitinibwithin in vivo models of metastasis, " Angiogenesis, vol. 15, no. 4, pp. 623-641, 2012.
23. J. Hu, F. Bianchi, M. Ferguson, et al., "Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer, " Oncogene, vol. 24, no. 7, pp. 1212-1219, 2005.
24. F. Stessels, G. van den Eynden, I. van der Auwera, et al., "Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia, " British Journal of Cancer, vol. 90, no. 7, pp. 1429-1436, 2004.
25. J. H. Caduff, L. C. Fischer, and P. H. Burri, "Scanning electron microscope study of the developing microvasculature in the postnatal rat lung, " Anatomical Record, vol. 216, no. 2, pp. 154-164, 1986.
26. S. Patan, L. L. Munn, and R. K. Jain, "Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis, " Microvascular Research, vol. 51, no. 2, pp. 260-272, 1996.
27. R. Hlushchuk, O. Riesterer, O. Baum, et al., "Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation, " American Journal of Pathology, vol. 173, no. 4, pp. 1173-1185, 2008.
28. V. Djonov, O. Baum, and P. H. Burri, "Vascular remodeling by intussusceptive angiogenesis, " Cell and Tissue Research, vol. 314, no. 1, pp. 107-117, 2003.
29. V. Djonov, M. Schmid, S. A. Tschanz, and P. H. Burri, "Intussusceptive angiogenesis: its role in embryonic vascular network formation, " Circulation Research, vol. 86, no. 3, pp. 286-292, 2000.
30. A. Collen, R. Hanemaaijer, F. Lupu, et al., "Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrincollagen matrix, " Blood, vol. 101, no. 5, pp. 1810-1817, 2003.
31. G. W. Prager, J. M. Breuss, S. Steurer, J. Mihaly, and B. R. Binder, "Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells, " Blood, vol. 103, no. 3, pp. 955-962, 2004.
32. M. C. Brahimi-Horn, J. Chiche, and J. Pouysségur, "Hypoxia and cancer, " Journal of Molecular Medicine, vol. 85, no. 12, pp. 1301-1307, 2007.
33. B. Bao, A. S. Azmi, S. Ali, et al., "The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness, " Biochimica et BiophysicaActa, vol. 1826, no. 2, pp. 272-296, 2012.
34. M. K. Asiedu, J. N. Ingle, M. D. Behrens, D. C. Radisky, and K. L. Knutson, " TGFβ/TNFα-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype, " Cancer Research, vol. 71, no. 13, pp. 4707-4719, 2011.
35. E. D. Hay, "An overview of epithelio-mesenchymal transformation, " Acta Anatomica, vol. 154, no. 1, pp. 8-20, 1995.
36. H. Hugo, M. L. Ackland, T. Blick, et al., "Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression, " Journal of Cellular Physiology, vol. 213, no. 2, pp. 374-383, 2007.
37. A. M. Shannon, D. J. Bouchier-Hayes, C. M. Condron, and D. Toomey, "Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies, " Cancer Treatment Reviews, vol. 29, no. 4, pp. 297-307, 2003.
38. R. Schreck, K. Albermann, and P. A. Baeuerle, "Nuclear factor κβ: an oxidative stress-responsive transcription factor of eukaryotic cells (a review), " Free Radical Research Communications, vol. 17, no. 4, pp. 221-237, 1992.
39. A. C. Koong, E. Y. Chen, and A. J. Giaccia, "Hypoxia causes the activation of nuclear factor B through the phosphorylation of IκBβ on tyrosine residues, " Cancer Research, vol. 54, no. 6, pp. 1425-1430, 1994.
40. M. A. Huber, N. Azoitei, B. Baumann, et al., "NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression, " Journal of Clinical Investigation, vol. 114, no. 4, pp. 569-581, 2004.
41. Z. Cheng, B. Sun, S. Wang, et al., "Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1 activation in pancreatic cancer cells under hypoxic conditions, " PLoS ONE, vol. 6, no. 8, Article ID e23752, 2011.
42. W. Yan, Y. Fu, D. Tian, et al., "PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells, " Biochemical and Biophysical Research Communications, vol. 382, no. 3, pp. 631-636, 2009.
43. G. Lin, R. Gai, Z. Chen, et al., "The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-beta1, " European Journal of Pharmacology, vol. 729, pp. 45-53, 2014.
44. L. Miele, "Notch signaling, " Clinical Cancer Research, vol. 12, no. 4, pp. 1074-1079, 2006.
45. T. Ishida, H. Hijioka, K. Kume, A. Miyawaki, and N. Nakamura, "Notch signaling induces EMT in OSCC cell lines in a hypoxic environment, "Oncology Letters, vol. 6, no. 5, pp. 1201-1206, 2013.
46. J. Chen, N. Imanaka, and J. D. Griffin, "Hypoxia potentiates Notch signaling in breast cancer leading to decreased Ecadherin expression and increased cell migration and invasion, " British Journal of Cancer, vol. 102, no. 2, pp. 351-360, 2010.
47. R. Fodde and T. Brabletz, "Wnt/β-catenin signaling in cancer stemness and malignant behavior, " Current Opinion in Cell Biology, vol. 19, no. 2, pp. 150-158, 2007.
48. R. Nusse and H. E. Varmus, "Wnt genes, " Cell, vol. 69, no. 7, pp. 1073-1087, 1992.
49. C. Y. Logan and R. Nusse, "TheWnt signaling pathway in development and disease, " Annual Review of Cell and Developmental Biology, vol. 20, pp. 781-810, 2004.
50. Y. G. Jiang, Y. Luo, D. L. He, et al., "Role of Wnt/β-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1, " International Journal of Urology, vol. 14, no. 11, pp. 1034-1039, 2007.
51. S. K. To, W. J. Zeng, J. Z. Zeng, and A. S. Wong, "Hypoxia triggers aNur77-beta-catenin feed-forward loop to promote the invasive growth of colon cancer cells, " The British Journal of Cancer, vol. 110, no. 4, pp. 935-945, 2014.
52. L. Liu, X. Zhu, W. Wang, et al., "Activation of β-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis, " Clinical Cancer Research, vol. 16, no. 10, pp. 2740-2750, 2010.
53. M. P. Di Magliano and M. Hebrok, "Hedgehog signalling in cancer formation and maintenance, " Nature Reviews Cancer, vol. 3, no. 12, pp. 903-911, 2003.
54. Y. A. Yoo, M. H. Kang, H. J. Lee, et al., "Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer, " Cancer Research, vol. 71, no. 22, pp. 7061-7070, 2011.
55. J. Lei, J. Ma, Q. Ma, et al., "Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner, " Molecular Cancer, vol. 12, no. 1, article 66, 2013.
56. H. Onishi, M. Kai, S. Odate, et al., "Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer, " Cancer Science, vol. 102, no. 6, pp. 1144-1150, 2011.
57. A. J. Maniotis, R. Folberg, A. Hess, et al., "Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry, " The American Journal of Pathology, vol. 155, no. 3, pp. 739-752, 1999.
58. M. J. C. Hendrix, E. A. Seftor, A. R. Hess, and R. E. B. Seftor, "Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma, " Nature Reviews Cancer, vol. 3, no. 6, pp. 411-421, 2003.
59. R. Francescone, S. Scully, B. Bentley, et al., "Glioblastomaderived tumor cells induce vasculogenic mimicry through Flk-1 protein activation, " The Journal of Biological Chemistry, vol. 287, no. 29, pp. 24821-24831, 2012.
60. S. Scully, R. Francescone, M. Faibish, et al., "Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas, " Journal of Neuroscience, vol. 32, no. 37, pp. 12950-12960, 2012.
61. R. E. B. Seftor, E. A. Seftor, N. Koshikawa, et al., "Cooperative interactions of laminin 5 β2 chain, matrix metalloproteinase-2, andmembrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma, " Cancer Research, vol. 61, no. 17, pp. 6322-6327, 2001.
62. N. Zhao, B. C. Sun, T. Sun, et al., "Hypoxia-inducedvasculogenic mimicry formation via VE-cadherin regulation by Bcl-2, " Medical Oncology, vol. 29, no. 5, pp. 3599-3607, 2012.
63. A. R. Hess, E. A. Seftor, L. M. Gruman, M. S. Kinch, R. E. B. Seftor, and M. J. C. Hendrix, "VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry, " Cancer Biology and Therapy, vol. 5, no. 2, pp. 228-233, 2006.
64. D. W. J. van der Schaft, F. Hillen, P. Pauwels, et al., "Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia, " Cancer Research, vol. 65, no. 24, pp. 11520-11528, 2005.
65. N. Sharma, R. E. B. Seftor, E. A. Seftor, et al., "Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry, " Prostate, vol. 50, no. 3, pp. 189-201, 2002.
66. Y. S. Chen and Z. P. Chen, "Vasculogenic mimicry: a novel target for glioma therapy, " Chinese Journal of Cancer, vol. 33, no. 2, pp. 74-79, 2014.
67. C. I. M. Baeten, F. Hillen, P. Pauwels, A. P. de Bruine, and C. G. M. I. Baeten, "Prognostic role of vasculogenic mimicry in colorectal cancer, " Diseases of the Colon and Rectum, vol. 52, no. 12, pp. 2028-2035, 2009.
68. M. Wolk, "Considerations on the possible origins of fetal hemoglobin cells produced in developing tumors, " Stem Cells and Development, vol. 23, no. 8, pp. 791-795, 2014.
69. E. Szabo, S. Rampalli, R. M. Risueño, et al., "Direct conversion of human fibroblasts tomultilineage blood progenitors, " Nature, vol. 468, no. 7323, pp. 521-526, 2010.
70. S. Zhang, I. Mercado-Uribe, and J. Liu, "Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo, " Cancer Letters, vol. 333, no. 2, pp. 205-212, 2013.
71. S. Zhang, I. Mercado-Uribe, and J. Liu, "Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel, " International Journal of Cancer, vol. 134, no. 3, pp. 508-518, 2014.
72. T. Yang, K. Rycaj, Z. Liu, and D. G. Tang, "Cancer stem cells: constantly evolving and functionally heterogeneous therapeutic targets, " Cancer Research, vol. 74, no. 11, pp. 2922-2927, 2014.
73. M. Castedo, J. Perfettini, T. Roumier, K. Andreau, R. Medema, and G. Kroemer, "Cell death bymitotic catastrophe: amolecular definition, " Oncogene, vol. 23, no. 16, pp. 2825-2837, 2004.
74. D. Zhang, Y. Wang, and S. Zhang, "Asymmetric cell division in polyploid giant cancer cells and low eukaryotic cells, " BioMed Research International, vol. 2014, Article ID 432652, 8 pages, 2014.
75. J. Erenpreisa and M. S. Cragg, "Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal, " Cancer Cell International, vol. 13, no. 1, article 92, 2013.
76. Y. Qu, L. Zhang, Z. Rong, T. He, and S. Zhang, "Number of glioma polyploid giant cancer cells (PGCCs) associated with vasculogenic mimicry formation and tumor grade in human glioma, " Journal of Experimental & Clinical Cancer Research, vol. 32, no. 1, p. 75, 2013.
77. T. M. Illidge, M. S. Cragg, B. Fringes, P. Olive, and J. A. Erenpreisa, "Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage, " Cell Biology International, vol. 24, no. 9, pp. 621-633, 2000.
78. S. Zhang, I. Mercado-Uribe, Z. Xing, B. Sun, J. Kuang, and J. Liu, "Generation of cancer stem-like cells through the formation of polyploid giant cancer cells, " Oncogene, vol. 33, no. 1, pp. 116-128, 2014.